Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide [Original Articles]

Conclusions
This is the first study to evaluate elamipretide in heart failure with reduced ejection fraction and demonstrates that a single infusion of elamipretide is safe and well tolerated. High-dose elamipretide resulted in favorable changes in left ventricular volumes that correlated with peak plasma concentrations, supporting a temporal association and dose–effect relationship. Further study of elamipretide is needed to determine long-term safety and efficacy.

Clinical Trial Registration
URL: https://www.clinicaltrials.gov. Unique identifier: NCT02388464.

Source: Circulation: Heart Failure - December 7, 2017 Category: Cardiology Authors: Daubert, M. A., Yow, E., Dunn, G., Marchev, S., Barnhart, H., Douglas, P. S., OConnor, C., Goldstein, S., Udelson, J. E., Sabbah, H. N. Tags: Metabolism, Cardiomyopathy, Heart Failure Original Articles Source Type: research